公开(公告)号：US20190144555A1

公开(公告)日：2019-05-16

申请号：US16091456

申请日：2017-04-04

Applicant: UNIVERSITÄT STUTTGART ,  BALIOPHARM AG

Inventor： Roland KONTERMANN ,  Klaus PFIZENMAIER ,  Fabian RICHTER ,  Kirstin ZETTLITZ ,  Peter SCHEURICH ,  Andreas HERRMANN

IPC: C07K16/28 ,  A61P37/06

CPC classification number: C07K16/2878 ,  A61P37/06 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.

公开(公告)号：US20210395323A1

公开(公告)日：2021-12-23

申请号：US17465186

申请日：2021-09-02

Applicant: UNIVERSITÄT STUTTGART

Inventor： Roman FISCHER ,  Roland KONTERMANN ,  Klaus PFIZENMAIER ,  Martin SIEGEMUND

IPC: C07K14/525

Abstract: The present invention relates to a tumor necrosis factor receptor (TNFR) binding protein complex comprising 12 or more N protein ligands (PLs) that specifically bind to the extracellular part of the same TNFR. Preferably, the TNFR binding protein complex binds to the extracellular part of TNFR2. Preferably, the TNFR binding protein complex of the present invention further comprises a two or more polymerization domains (PD).

公开(公告)号：US20180094059A1

公开(公告)日：2018-04-05

申请号：US15558372

申请日：2016-03-18

Applicant: UNIVERSITÄT STUTTGART ,  BIONTECH AG

Inventor： Ugur SAHIN ,  Roland KONTERMANN ,  Klaus PFIZENMAIER ,  Martin SIEGEMUND ,  Meike HUTT ,  Oliver SEIFERT

IPC: C07K16/28 ,  C07K16/32 ,  C07K14/705

CPC classification number: C07K16/2863 ,  C07K14/70575 ,  C07K16/32 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/91

Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector. Further, the present invention relates to said polypeptides, said nucleic acid or said vector for the use as a medicament or for the use in the diagnosis, prophylaxis or treatment of hyperproliferative disorders and inflammatory disorders.